Literature DB >> 16023057

Fragment-based lead discovery: leads by design.

Robin A E Carr1, Miles Congreve, Christopher W Murray, David C Rees.   

Abstract

Fragment-based lead discovery (also referred to as needles, shapes, binding elements, seed templates or scaffolds) is a new lead discovery approach in which much lower molecular weight (120-250 Da) compounds are screened relative to HTS campaigns. Fragment-based hits are typically weak inhibitors (10 microM-mM), and therefore need to be screened at higher concentration using very sensitive biophysical detection techniques such as protein crystallography and NMR as the primary screening techniques, rather than bioassays. Compared with HTS hits, these fragments are simpler, less functionalized compounds with correspondingly lower affinity. However, fragment hits typically possess high 'ligand efficiency' (binding affinity per heavy atom) and so are highly suitable for optimization into clinical candidates with good drug-like properties.

Mesh:

Year:  2005        PMID: 16023057     DOI: 10.1016/S1359-6446(05)03511-7

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  89 in total

1.  Small molecules containing hetero-bicyclic ring systems compete with UDP-Glc for binding to WaaG glycosyltransferase.

Authors:  Jens Landström; Karina Persson; Christoph Rademacher; Magnus Lundborg; Warren Wakarchuk; Thomas Peters; Göran Widmalm
Journal:  Glycoconj J       Date:  2012-06-19       Impact factor: 2.916

2.  Screening a fragment cocktail library using ultrafiltration.

Authors:  Sayaka Shibata; Zhongsheng Zhang; Konstantin V Korotkov; Jaclyn Delarosa; Alberto Napuli; Angela M Kelley; Natasha Mueller; Jennifer Ross; Frank H Zucker; Frederick S Buckner; Ethan A Merritt; Christophe L M J Verlinde; Wesley C Van Voorhis; Wim G J Hol; Erkang Fan
Journal:  Anal Bioanal Chem       Date:  2011-07-13       Impact factor: 4.142

Review 3.  Ligand discovery and virtual screening using the program LIDAEUS.

Authors:  P Taylor; E Blackburn; Y G Sheng; S Harding; K-Y Hsin; D Kan; S Shave; M D Walkinshaw
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

4.  Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide.

Authors:  Sameer Kawatkar; Hongming Wang; Ryszard Czerminski; Diane Joseph-McCarthy
Journal:  J Comput Aided Mol Des       Date:  2009-06-03       Impact factor: 3.686

5.  Docking for fragment inhibitors of AmpC beta-lactamase.

Authors:  Denise G Teotico; Kerim Babaoglu; Gabriel J Rocklin; Rafaela S Ferreira; Anthony M Giannetti; Brian K Shoichet
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-22       Impact factor: 11.205

6.  CONFIRM: connecting fragments found in receptor molecules.

Authors:  David C Thompson; R Aldrin Denny; Ramaswamy Nilakantan; Christine Humblet; Diane Joseph-McCarthy; Eric Feyfant
Journal:  J Comput Aided Mol Des       Date:  2008-07-09       Impact factor: 3.686

Review 7.  Docking Screens for Novel Ligands Conferring New Biology.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

8.  In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens.

Authors:  Waleed Younis; Ahmed AbdelKhalek; Abdelrahman S Mayhoub; Mohamed N Seleem
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 9.  Perspectives on NMR in drug discovery: a technique comes of age.

Authors:  Maurizio Pellecchia; Ivano Bertini; David Cowburn; Claudio Dalvit; Ernest Giralt; Wolfgang Jahnke; Thomas L James; Steve W Homans; Horst Kessler; Claudio Luchinat; Bernd Meyer; Hartmut Oschkinat; Jeff Peng; Harald Schwalbe; Gregg Siegal
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

Review 10.  Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions.

Authors:  Leah N Makley; Jason E Gestwicki
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.